Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus
Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.
You may also be interested in...
The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.
Benlysta was an early pioneer in systemic lupus erythematosus, but GSK now plans to expand the drug into the acute area, active lupus nephritis, with a filing in 2020.
The latest drug development news and highlights from our US FDA Performance Tracker.